Max Schlueter

Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden

Nathaniel Henry, Jelena Jovanović, Max Schlueter et al. · Journal of Medical Economics · 2017 · 32 citations · Full text

Pharmacy, Hematology, Pharmacoeconomics +12

Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception

Nathaniel Henry, Max Schlueter, Julia Lowin et al. · Journal of Family Planning and Reproductive Health Care · 2014 · 31 citations · Full text

Medicine, Obstetrics, Pharmacoeconomics +17

The cost of cancer – A comparative analysis of the direct medical costs of cancer and other major chronic diseases in Europe

Max Schlueter, Katie Chan, Romain Lasry et al. · PLoS ONE · 2020 · 28 citations · Full text

Social Sciences, Oncology, Pharmacoeconomics +17

Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK

G. Vega-Hernández, Radek Wojcik, Max Schlueter · Diabetes Therapy · 2017 · 21 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

<p>Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain</p>

Max Schlueter, Elaine Finn, Silvia Díaz‐Cerezo et al. · ClinicoEconomics and Outcomes Research · 2019 · 11 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17